Want to see DNTH full AI Analyst Report?
DNTH Stock Chart & Stats
$103.87
-$0.92(-0.88%)
At close: 4:00 PM EDT
$103.87
-$0.92(-0.88%)
Day’s Range― - ―
52-Week Range$18.08 - $114.55
Previous CloseN/A
Volume827.63K
Average Volume (3M)1.23M
Market Cap
$5.84B
Enterprise Value$2.92K
Total Cash (Recent Filing)$886.81M
Total Debt (Recent Filing)$1.29M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Nov 05, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.77
Shares Outstanding54,666,233
10 Day Avg. Volume895,608
30 Day Avg. Volume1,227,272
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)3.16
Price to Sales (P/S)764.98
P/FCF Ratio-12.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$140.00Price Target Upside34.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-3.75
Revenue Forecast (FY)$1.19M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt and expanding equity/assets reduce financial risk and give management runway to fund clinical programs without immediate refinancing. This balance-sheet strength supports multi-year R&D plans and strategic flexibility across the next several quarters.
Clinical Proof-of-ConceptA 75% responder rate in a Phase 3 interim analysis is a durable clinical validation that can materially de‑risk the lead program, aid regulatory discussions, and strengthen competitive positioning in neuromuscular biologics, supporting longer-term commercial potential.
Broad Pipeline And MilestonesMultiple programs (claseprubart EMERGE, DNTH212, DNTH312) and an ample cash position provide sequenced catalysts and optionality. The breadth and cash runway reduce single‑asset exposure and support sustained development and value creation over the medium term.
Bears Say
Rising Cash BurnMaterially increasing negative operating cash flow shows growing cash consumption as trials advance. Even with strong cash today, continued higher burn elevates financing risk and could force program prioritization or dilution if milestones take longer or costs rise.
Persistent Operating LossesSustained, widening operating losses indicate the company remains far from profitable operations. Over the medium term this compresses free cash flow, limits reinvestment without external funding, and raises the likelihood of additional capital raises that dilute equity holders.
Small, Volatile Revenue BaseLimited and declining revenue underscores lack of commercial diversification—revenues are insufficient to offset R&D spending. This structural scale gap means the business remains dependent on trial outcomes and financing, increasing execution risk over the next several quarters.
Dianthus Therapeutics News
DNTH FAQ
What was Dianthus Therapeutics’s price range in the past 12 months?
Dianthus Therapeutics lowest stock price was $18.08 and its highest was $114.55 in the past 12 months.
What is Dianthus Therapeutics’s market cap?
Dianthus Therapeutics’s market cap is $5.84B.
When is Dianthus Therapeutics’s upcoming earnings report date?
Dianthus Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 91 days.
How were Dianthus Therapeutics’s earnings last quarter?
Dianthus Therapeutics released its earnings results on Aug 04, 2026. The company reported -$0.9 earnings per share for the quarter, missing the consensus estimate of -$0.846 by -$0.054.
Is Dianthus Therapeutics overvalued?
According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued.
Does Dianthus Therapeutics pay dividends?
Dianthus Therapeutics does not currently pay dividends.
What is Dianthus Therapeutics’s EPS estimate?
Dianthus Therapeutics’s EPS estimate is -1.02.
How many shares outstanding does Dianthus Therapeutics have?
Dianthus Therapeutics has 54,666,233 shares outstanding.
What happened to Dianthus Therapeutics’s price movement after its last earnings report?
Dianthus Therapeutics reported an EPS of -$0.9 in its last earnings report, missing expectations of -$0.846. Following the earnings report the stock price went up 1.902%.
Which hedge fund is a major shareholder of Dianthus Therapeutics?
Currently, no hedge funds are holding shares in DNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dianthus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$140.00 (34.78% Upside)
$140.00 (34.78% Upside)
Blogger Sentiment
Neutral
DNTH Sentiment 50%
Sector Average 64%
Sector Average 64%
Hedge Fund Trend
Increased
By 3.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
386.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
257.70%
Trailing 12-Months
Company Description
Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
DNTH Stock 12 Month Forecast
Average Price Target
$140.00
▲(34.78% Upside)
Technical Analysis
Ardelyx
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Amylyx Pharmaceuticals Inc
―
Biohaven Ltd.
―
Ownership Overview
0.13% Insiders
26.12% Mutual Funds
3.80% Other Institutional Investors
57.25% Public Companies and
Individual Investors